Blockade by agmatine of catecholamine release from chromaffin cells is unrelated to imidazoline receptors.
The blockade of exocytosis induced by the putative endogenous ligand for imidazoline receptors, agmatine, was studied by using on-line measurement of catecholamine release in bovine adrenal medullary chromaffin cells. Agmatine inhibited the acetylcholine-evoked release of catecholamines in a concentration-dependent manner (IC(50)=366 microM); the K(+)-evoked release of catecholamines was unaffected. Clonidine (100 microM) and moxonidine (100 microM) also inhibited by 75% and 50%, respectively, the acetylcholine-evoked response. In cells voltage-clamped at -80 mV, the intermittent application of acetylcholine pulses elicited whole-cell inward currents (I(ACh)) that were blocked 63% by 1 mM agmatine. The onset of blockade was very fast (tau(on) = 31 ms); the recovery of the current after washout of agmatine also occurred very rapidly (tau(off = 39 ms). Efaroxan (10 microM) did not affect the inhibition of I(ACh) elicited by 1 mM agmatine. I(ACh) was blocked 90% by 100 microM clonidine and 50% by 100 microM moxonidine. The concentration-response curve for acetylcholine to elicit inward currents was shifted to the right in a non-parallel manner by 300 microM agmatine. The blockade of I(ACh) caused by agmatine (100 microM) was similar at various holding potentials, around 50%. When intracellularly applied, agmatine did not block I(ACh). At 1 mM, agmatine blocked I(Na) by 23%, I(Ba) by 14%, I(K(Ca)) by 16%, and I(K(VD)) by 18%. In conclusion, agmatine blocks exocytosis in chromaffin cells by blocking nicotinic acetylcholine receptor currents. In contrast to previous views, these effects seem to be unrelated to imidazoline receptors.
Santos
W C
WC
Departamento de Farmacología, Escola Paulista de Medicina, UNIFESP, 04034-970, SP, Sao Paulo, Brazil.
Hernández-Guijo
J M
JM
Ruiz-Nuño
A
A
Olivares
R
R
Jurkiewicz
A
A
Gandía
L
L
García
A G
AG
D000109:Acetylcholine / Q000494:pharmacology; D000376:Agmatine / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D002395:Catecholamines / Q000378:metabolism*; D002417:Cattle; D002478:Cells, Cultured; D019439:Chromaffin Cells / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D003000:Clonidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D007093:Imidazoles / Q000494:pharmacology; D054755:Imidazoline Receptors; D008564:Membrane Potentials / Q000187:drug effects; D011188:Potassium / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011955:Receptors, Drug / Q000502:physiology*; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D015222:Sodium Channels / Q000187:drug effects / Q000502:physiology
D001572:Benzofurans; D015220:Calcium Channels; D002395:Catecholamines; D007093:Imidazoles; D054755:Imidazoline Receptors; D015221:Potassium Channels; D011955:Receptors, Drug; D011978:Receptors, Nicotinic; D015222:Sodium Channels; D000376:Agmatine; C043482:moxonidine; C062597:efaroxan; D003000:Clonidine; D000109:Acetylcholine; D011188:Potassium